Bengaluru : Mankind Pharma (BSE: 543904 | NSE: MANKIND) India’s fourth largest pharmaceutical Company today announced its financial results for the first quarter ended 30th June 2025. The information mentioned in this release is based on consolidated financial statements.

Mr. Rajeev Juneja – Vice Chairman & Managing Director

“Mankind’s revenue grew by 24.5% with EBITDA margins at 23.8% in Q1FY26 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation.

Visible encouraging trends with 1.8x volume growth to IPM led by outperformance in Anti-infectives & Respiratory segment – apart from continued outperformance in Cardiology and Anti Diabetics.

BSV growth initiatives are making steady progress and we remain confident of delivering healthy performance this year onwards.

As we celebrate 30 years of our operations, we would like our shareholders to be part of this milestone therefore the Company’s Board has approved an interim dividend of Rs 1 per share.”

Q1 FY26 Performance Summary –

  • Revenue from Operations at INR 3,570 Cr, up by 24.5% YoY
    • Domestic revenue at INR 3,101 Cr, up 18.9%, Exports at INR 469 Cr, up 81.1% YoY
  • EBITDA margin of 23.8% up by 20 bps YoY and PAT margin of 12.5%
  • Diluted EPS1 of INR 10.6 down by 20.1% YoY (FV Re.1)

Diluted EPS not annualised